Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
REDWOOD CITY, Calif., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Oppenheimer 26th Annual Healthcare Conference on December 8, 2015 at 2:10 p.m. ET.
To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at http://investor.relypsa.com/events.cfm.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, VeltassaTM (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Alex Dobbin
Associate Director, Investor Relations
650-421-9687
[email protected]
